By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...
Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...
The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Hosted on MSN
Why I wouldn't touch Novavax with a 10-foot pole
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...
CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...
Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, although it noted that the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results